BioVie Inc. (BIVI)
BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease and Phase I clinical trial for the treatment of Parkinson's disease. The company is also developing NE3107, which is in pre-clinical stage for the treatment of multiple myeloma and prostate cancer. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is based in Carson City, Nevada.
$17.31M
Mr. Cuong Viet Do M.B.A., MBA
13.00
Carson City, NV
Jan 14, 2014
-0.30
$-9.30
2.43
2.45
0.00%
-3.64
-0.05
6.98
0.00
2.45
-114.22%
-294.42%
Similar stocks (8)
Day One Biopharmaceuticals, Inc.
DAWN
Terns Pharmaceuticals, Inc.
TERN
Inozyme Pharma, Inc.
INZY
Amylyx Pharmaceuticals, Inc.
AMLX
HOOKIPA Pharma Inc.
HOOK
Acumen Pharmaceuticals, Inc.
ABOS
X4 Pharmaceuticals, Inc.
XFOR
Eledon Pharmaceuticals, Inc.
ELDN
ETF Exposure (5)
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Total Stock Market Index Fund
VITSX
0%
Vanguard Total Stock Market Index Fund
VTI
0%
Vanguard Total Stock Market Index Fund
VTSAX
0%
Vanguard Extended Market Index Fund
VXF
0%
Similar stocks (8)
Day One Biopharmaceuticals, Inc.
DAWN
Terns Pharmaceuticals, Inc.
TERN
Inozyme Pharma, Inc.
INZY
Amylyx Pharmaceuticals, Inc.
AMLX
HOOKIPA Pharma Inc.
HOOK
Acumen Pharmaceuticals, Inc.
ABOS
X4 Pharmaceuticals, Inc.
XFOR
Eledon Pharmaceuticals, Inc.
ELDN
ETF Exposure (5)
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Total Stock Market Index Fund
VITSX
0%
Vanguard Total Stock Market Index Fund
VTI
0%
Vanguard Total Stock Market Index Fund
VTSAX
0%
Vanguard Extended Market Index Fund
VXF
0%